Aerie Pharmaceuticals reported a net loss of $47.2 million, or $1.04 per share, in the second quarter of 2019 compared with a net loss of $55 million, or $1.40 per share, in the same quarter of 2018, according to a press release.
Operating expenses totaled $61.2 million, including $34.5 million in selling, general and administrative expenses, $5.8 million in preapproval commercial manufacturing expenses and $20.9 in research and development expenses.
Net product revenues were $15.8 million, consisting of combined sales of Rhopressa (netarsudil 0.02% ophthalmic solution), which was launched in
Uncategorized